FDA decision: Brepocitinib by Priovant Therapeutics (in 2026)

Health & MedicineOne-Off5m

KalshiVerifica disponibilitàKYC richiesto2% di commissioneDati di risoluzione verificatiCalibrazione approssimativa

Probabilità implicita attuale

Sì 98%

Qualita del mercato

44 / 100

Bassa qualità

Volume 24h

0 €

Liquidità

922,9 €

Bassa liquidità

Bid / Ask

80.0% / 86.0%

Spread

6.0 pt

Spread ampio

Dati di mercato

Aggiornato 22 minuti fa

17 giu 26, 21:001 gen 27, 4:59

Trend

Esito24hProbabilità

Solo fondi simulati, nessun denaro realeNon è consulenza finanziaria

Esito scelto

Yes98%

Puntata (USDT)

Regole

If the FDA's decision on Brepocitinib by Priovant Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
Brepocitinib is an experimental oral pill developed by Priovant Therapeutics that is designed to calm an overactive immune system in people with certain inflammatory diseases.
Think of it like a circuit breaker for runaway immune signals: it blocks specific molecular switches inside immune cells that, when left unchecked, drive damaging inflammation throughout the body.
In the VALOR trial , it is being tested as a treatment for dermatomyositis, a rare disease in which the immune system attacks the body's own muscles and skin.

Trend del volume

$812

3 lug10g di dati26 lug

Mercati Correlati

Hantavirus pandemic in 2026?

91K €

Sì: 3%

POLYMARKET

# of views of MrBeast video day 3?

12,9K €

26-27M: 93%

POLYMARKET

Ebola pandemic in 2026?

4,9K €

Sì: 3%

POLYMARKET

Measles cases in 2026?

Pandemic in 2026?

Cyclosporiasis cases reported in the US in 2026?

1,2K €

Above 20k: 34%

KALSHI

Attivi in questi argomenti

BitcoinBTC$63,338.67-2.91%

EthereumETH$1,875.51-4.52%

SolanaSOL$73.19-4.29%

DogecoinDOGE$0.0701-3.67%

XRPXRP$1.05-4.88%

BNBBNB$565.62-1.13%

Notizie Correlate

NVIDIA BioNeMo Toolkit Accelerates AI-Driven Drug DiscoveryBlockchain.News

OpenAI Launches GeneBench-Pro to Test AI in BiologyBlockchain.News

Google Transfers Open Health Stack to Linux FoundationBlockchain.News

Regole

If the FDA's decision on Brepocitinib by Priovant Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
Brepocitinib is an experimental oral pill developed by Priovant Therapeutics that is designed to calm an overactive immune system in people with certain inflammatory diseases.
Think of it like a circuit breaker for runaway immune signals: it blocks specific molecular switches inside immune cells that, when left unchecked, drive damaging inflammation throughout the body.
In the VALOR trial , it is being tested as a treatment for dermatomyositis, a rare disease in which the immune system attacks the body's own muscles and skin.

FDA decision: Brepocitinib by Priovant Therapeutics (in 2026)

Health & MedicineOne-Off5m

KalshiVerifica disponibilitàKYC richiesto2% di commissioneDati di risoluzione verificatiCalibrazione approssimativa

Probabilità implicita attuale

Sì 98%

Qualita del mercato

44 / 100

Bassa qualità

Volume 24h

0 €

Liquidità

922,9 €

Bassa liquidità

Bid / Ask

80.0% / 86.0%

Spread

6.0 pt

Spread ampio

Dati di mercato

Aggiornato 22 minuti fa

17 giu 26, 21:001 gen 27, 4:59

Trend

Esito24hProbabilità

Solo fondi simulati, nessun denaro realeNon è consulenza finanziaria

Esito scelto

Yes98%

Puntata (USDT)

Regole

If the FDA's decision on Brepocitinib by Priovant Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
Brepocitinib is an experimental oral pill developed by Priovant Therapeutics that is designed to calm an overactive immune system in people with certain inflammatory diseases.
Think of it like a circuit breaker for runaway immune signals: it blocks specific molecular switches inside immune cells that, when left unchecked, drive damaging inflammation throughout the body.
In the VALOR trial , it is being tested as a treatment for dermatomyositis, a rare disease in which the immune system attacks the body's own muscles and skin.

Trend del volume

$812

3 lug10g di dati26 lug

Mercati Correlati

Hantavirus pandemic in 2026?

91K €

Sì: 3%

POLYMARKET

# of views of MrBeast video day 3?

12,9K €

26-27M: 93%

POLYMARKET

Ebola pandemic in 2026?

4,9K €

Sì: 3%

POLYMARKET

Measles cases in 2026?

Pandemic in 2026?

Cyclosporiasis cases reported in the US in 2026?

1,2K €

Above 20k: 34%

KALSHI

Attivi in questi argomenti

BitcoinBTC$63,338.67-2.91%

EthereumETH$1,875.51-4.52%

SolanaSOL$73.19-4.29%

DogecoinDOGE$0.0701-3.67%

XRPXRP$1.05-4.88%

BNBBNB$565.62-1.13%

Notizie Correlate

NVIDIA BioNeMo Toolkit Accelerates AI-Driven Drug DiscoveryBlockchain.News

OpenAI Launches GeneBench-Pro to Test AI in BiologyBlockchain.News

Google Transfers Open Health Stack to Linux FoundationBlockchain.News

Regole

If the FDA's decision on Brepocitinib by Priovant Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
Brepocitinib is an experimental oral pill developed by Priovant Therapeutics that is designed to calm an overactive immune system in people with certain inflammatory diseases.
Think of it like a circuit breaker for runaway immune signals: it blocks specific molecular switches inside immune cells that, when left unchecked, drive damaging inflammation throughout the body.
In the VALOR trial , it is being tested as a treatment for dermatomyositis, a rare disease in which the immune system attacks the body's own muscles and skin.